Vor Biopharma Inc. (VOR) stock
VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.18−0.79 (-4.16%)
Close on Nov 17, 2026Market cap $1.12BP/E –Yield –
Vor Biopharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Vor Biopharma's operating cash flow for the twelve months ending Sep 30, 2026 was -$119.17M. For fiscal 2025 it was -$142.71M. The highest annual figure on record is -$36.29M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$142.71M | – |
| FY2024 | Dec 31, 2024 | -$99.66M | – |
| FY2023 | Dec 31, 2023 | -$100.29M | – |
| FY2022 | Dec 31, 2022 | -$85.14M | – |
| FY2021 | Dec 31, 2021 | -$69.14M | – |
| FY2020 | Dec 31, 2020 | -$36.29M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$32.75M | – |
| Q2 FY2026 | Jun 30, 2026 | -$25.38M | – |
| Q1 FY2026 | Mar 31, 2026 | -$38.25M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$53.66M | – |
| Q2 FY2025 | Jun 30, 2025 | -$35.18M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.07M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.06M | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.29M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.85M | – |
| Q1 FY2024 | Mar 31, 2024 | -$30.47M | – |
| Q4 FY2023 | Dec 31, 2023 | -$24.03M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.90M | – |
| Q2 FY2023 | Jun 30, 2023 | -$24.10M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.27M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.35M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.90M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$22.90M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.59M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.34M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.57M | – |
| Q1 FY2021 | Mar 31, 2021 | -$17.65M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.63M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.25M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.33M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.09M | – |
See a number that looks wrong?